COMPOSITION AND METHOD FOR TREATING ITCHING, BURNING AND DISCOMFORT OF THE SKIN
US20200085902A1
2020-03-19
16/664,477
2019-10-25
Abstract:
A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis (aloe vera) leaf gel, Camellia sinensis leaf (green tea) extract, Hamamelis virginiana (witch hazel) extract, tocopheryl acetate (vitamin E), and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.
Interested in similar patents?
Get notified when new applications in this technology area are published.
Classification:
A61K9/0014 » CPC further
Medicinal preparations characterised by special physical form; Galenical forms characterised by the site of application Skin, i.e. galenical aspects of topical compositions
A61K36/886 » CPC main
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines; Magnoliophyta (angiosperms); Liliopsida (monocotyledons) Aloeaceae (Aloe family), e.g. aloe vera
A61K31/573 » CPC further
Medicinal preparations containing organic active ingredients; Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K36/185 » CPC further
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines; Magnoliophyta (angiosperms) Magnoliopsida (dicotyledons)
A61K47/06 » CPC further
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K9/00 IPC
Medicinal preparations characterised by special physical form
A61K36/82 » CPC further
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines; Magnoliophyta (angiosperms); Magnoliopsida (dicotyledons) Theaceae (Tea family), e.g. camellia
A61K9/06 » CPC further
Medicinal preparations characterised by special physical form Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of co-pending U.S. application Ser. No. 15/217,721, filed Jul. 22, 2016, expected to issue as U.S. Pat. No. 10,456,438 on Oct. 29, 2019.
FIELD OF THE INVENTION
The present invention generally relates to the treatment of pruritus, more specifically relates to topical composition and method for alleviating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
BACKGROUND
“Pruritus” refers to an unpleasant sensation on the skin that urges to scratch or rub the area in order to obtain relief. Pruritus is commonly characterized by generalized and localized itching. Itching may be caused as a clinical manifestation of localized skin disorder, systemic disease, scratch reaction, insect bite, sunburn, wound healing and exposure to irritants such as plant toxins, chemicals, microbial proteins, and/or additional external mechanical, thermal and electrical stimuli. Common types of itching include anal itch, chemical itch, eczema, (including seborrheic dermatitis) pruritus dermatitis, diabetic skin itch, aging skin itch, foot-itch, jock itch, hives, dry winter skin itch and stress related scalp itch. Those who suffer from itch often note, persistent or recurrent attacks. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes. “Perianal itching” or “Pruritus ani” refers to the persistent itching and irritation of skin around the anus region. Perianal itching and burning not only causes physical discomfort but also results in distraction and socially awkward or embarrassing situations. Anal itching may be caused by chemical irritants in food, diarrhea, psoriasis, anal fissure, hemorrhoids, skin tags, diabetes, yeast infection and pinworm infection.
Current treatment options for localized pruritus including perianal itching involves the use of topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy. However, treatment with existing topical agents shows general but nonspecific benefit. Non-specific topical preparations including lotions, creams and oil-based ointments may provide softness and moisturizing effect on the dry skin, but causes an uncomfortable feeling and discomfort due to greasy nature of the preparation and soiling of garments. In addition, existing topical agents used for relieving perianal pruritus act slow and fail to provide complete cure from itching and burning.
Therefore, there is a need for an improved topical pharmaceutical preparation for providing rapid relief from pruritus by alleviating itching and burning in the perianal region of humans. There is also a need for improved composition and method for treating pruritus of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
SUMMARY OF THE INVENTION
The present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.
In an embodiment, the present invention relates to a composition for treating localized pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel (0-50%), Hamamelis virginiana extract (0-50%), deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol in amounts up to 3 percent by weight.
In an embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract, 0 to 3% deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
In an embodiment, the present invention relates to a topical composition for treating discomfort of the skin and/or mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The hydrocortisone is present in an amount up to 1 percent by weight. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight.
In an embodiment, the present invention relates to a pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream. The aloe leaf gel and witch hazel extract are both present in an amount up to 50 percent by weight. The green tea leaf extract and vitamin E are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The terms “active agent,” “drug”, “active compound” and “pharmacologically active agent” are used interchangeably herein to refer to a chemical material or compound which, when administered to humans, induces a desired pharmacologic effect. Included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect.
“Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids; acid addition salts formed with organic acids; or salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, aluminum ion; or coordinates with an organic base such as ethanolamine, and the like.
Pharmaceutically acceptable “carrier” or “carrier” is composed of materials that are present in pharmaceutical formulation other than the active ingredient. Carriers are considered safe and effective and may be administered to an individual without causing undesirable biological side effects. The term “carrier” includes, but is not limited to, excipients, diluents, binders, lubricants, disintegrators, fillers, gliding agent and coating compositions.
The present invention relates to a pharmaceutical composition for treating anal pruritus. The pharmaceutical composition comprises at least one active agent or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier. The composition is used for rapidly alleviating external anal itching and burning in humans.
In an embodiment, the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe leaf gel, deionized water, C12-15 alkyl benzoate, Green tea leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Witch Hazel extract, Sunflower seed oil, polyethylene glycol(PEG)-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate (Vitamin E), Zemea propanediol and hydrocortisone.
In an embodiment, the Aloe leaf gel of the composition is obtained from Aloe barbadensis leaves. Green tea leaf extract is obtained from Camellia sinensis leaves. Witch Hazel extract comprises an extract of Hamamelis virginiana and Sunflower seed oil is obtained from Helianthus annus seeds.
The present invention relates to a composition for treating localized anal pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel, and Hamamelis virginiana extract are in amounts up to 50 percent by weight. Other components such as deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol are in amounts up to 3 percent by weight.
In another embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract and 0 to 3% by weight deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
The composition is prepared in a form suitable for topical application on the skin surface of perianal region. The composition can be prepared in the form of cream, spray, lotion, solution, gel, emollient, ointment and aerosol form for application on the external perianal area of human body in order to alleviate itching.
EXAMPLE 1
In this exemplary embodiment, the composition of the present invention is formulated in the form of a topical cream, which comprises the active agent and pharmaceutically acceptable carriers in a specific percent by weight ratio as mentioned in Table 1.
| TABLE 1 | |
| Ingredient | Ratio (Percent by Ingredient Weight) |
| Hydrocortisone | 0 to 1 |
| Hamamelis virginiana extract |  0 to 50 |
| Camellia sinensis leaf extract | 0 to 3 |
| Tocopheryl acetate (Vitamin E) | 0 to 3 |
| Aloe barbadensis juice |  0 to 50 |
| Helianthus annuus seed oil | 0 to 3 |
| Cetyl alcohol | 0 to 3 |
| Glycerin stearate | 0 to 3 |
| Ceteareth-20 | 0 to 3 |
| Stearyl alcohol | 0 to 3 |
| C12-15 alkyl benzoate | 0 to 3 |
| Cetearyl alcohol | 0 to 3 |
| Zemea propanediol | 0 to 3 |
| Phenoxyethanol | 0 to 3 |
| PEG-100 stearate | 0 to 3 |
| Ethylexylglycerin | 0 to 3 |
| Petrolatum | 0 to 3 |
| Aqua (deionized water) | 0 to 3 |
Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific examples and studies detailed above are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
Claims
What is claimed is:1. A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel.
2. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight.
3. The topical composition of claim 1 wherein the Hamamelis virginiana extract is present in an amount up to 50 percent by weight.
4. The topical composition of claim 1 wherein the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight.
5. The topical composition of claim 1 wherein the tocopheryl acetate is present in an amount up to 3 percent by weight.
6. The topical composition of claim 1 wherein hydrocortisone is present in an amount up to 1 percent by weight.
7. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight, the Hamamelis virginiana extract is present in an amount up to 50 percent by weight, the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight, the tocopheryl acetate is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
8. A pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream, lotion, emollient, ointment, spray, aerosol or gel.
9. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight.
10. The topical composition of claim 8 wherein the witch hazel extract is present in an amount up to 50 percent by weight.
11. The topical composition of claim 8 wherein the green tea leaf extract is present in an amount up to 3 percent by weight.
12. The topical composition of claim 8 wherein the vitamin E is present in an amount up to 3 percent by weight.
13. The topical composition of claim 8 wherein hydrocortisone is present in an amount up to 1 percent by weight.
14. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight, the witch hazel extract is present in an amount up to 50 percent by weight, the green tea leaf extract leaf extract is present in an amount up to 3 percent by weight, the vitamin E is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
15. A method for treating discomfort of the skin including the perianal and vaginal regions, the method comprising administering topically a pharmaceutical composition comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream.